D’fhógair cuideachta teicneolaíochta leighis atá dírithe ar theicneolaíochtaí nuálacha a fhorbairt le haghaidh diagnóis luath ailse, torthaí nua taighde inniu. Léirigh staidéar cliniciúil ar ailse ae an poitéinseal iontach atá ag bithmharcóir DNA meitilation-bhunaithe nua LAM chun carcanóma hepatocellular (HCC) a bhrath Is í an íogaireacht braite 95% agus is é 97.5% an sainiúlacht.
Sa staidéar seo, bailíodh samplaí stoic de 130 ábhar, lena n-áirítear: 60 ábhar a diagnóisíodh le carcinoma hepatocellular (céim I go IV), 30 ábhar gan galar ae, 10 n-ábhar a diagnóisíodh le galar ae neamhurchóideacha agus 30 ábhar a diagnóisíodh le hailse chíche, ailse cholaireicteach. nó ailse scamhóg. Baineadh DNA as an sampla, rinneadh an DNA a chlaochlú le bisulfite, agus rinneadh meitiliú DNA a chainníochtú ag baint úsáide as an ardán IvyGene. Tar éis bailiú sonraí agus anailís a dhéanamh ar na samplaí go léir, dall na samplaí chun an fheidhmíocht tástála a ríomh.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of ailse cholaireicteach samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
